Royal Bank of Canada Reaffirms “Outperform” Rating for Jasper Therapeutics (NASDAQ:JSPR)

Royal Bank of Canada reiterated their outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note published on Monday morning,Benzinga reports. The brokerage currently has a $68.00 price target on the stock.

A number of other research analysts also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Evercore ISI reiterated an “outperform” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Finally, JMP Securities reiterated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, October 15th. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $73.38.

Jasper Therapeutics Stock Up 2.5 %

JSPR stock opened at $22.12 on Monday. The firm has a market cap of $331.82 million, a price-to-earnings ratio of -4.67 and a beta of 2.18. The company’s fifty day simple moving average is $21.74 and its 200 day simple moving average is $20.67. Jasper Therapeutics has a 12-month low of $5.02 and a 12-month high of $31.01.

Institutional Trading of Jasper Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Barclays PLC grew its holdings in shares of Jasper Therapeutics by 320.7% during the third quarter. Barclays PLC now owns 16,146 shares of the company’s stock valued at $304,000 after buying an additional 12,308 shares during the last quarter. Jane Street Group LLC bought a new position in Jasper Therapeutics in the 3rd quarter valued at about $251,000. Wellington Management Group LLP bought a new position in Jasper Therapeutics in the 3rd quarter valued at about $447,000. State Street Corp boosted its stake in Jasper Therapeutics by 12.3% during the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after purchasing an additional 23,564 shares during the last quarter. Finally, Samsara BioCapital LLC increased its holdings in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.